Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements
Moves To Reduce Data Burden Allow Smaller Trial For Keytruda Rival
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
